公开(公告)号：US20250017946A1

公开(公告)日：2025-01-16

申请号：US18707761

申请日：2022-11-07

Applicant: Amylyx Pharmaceuticals, Inc.

Inventor： Joshua Cohen ,  Justin Klee

IPC: A61K31/575 ,  A61K31/13 ,  A61K31/192 ,  A61K31/27 ,  A61K31/473 ,  A61K31/55 ,  A61P25/28

Abstract: Provided herein are methods and compositions for treating a neurodegenerative disease (e.g., AD or PSP). The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

公开(公告)号：US20250000814A1

公开(公告)日：2025-01-02

申请号：US18688439

申请日：2022-09-01

Applicant: DONG-A ST CO., LTD.

Inventor： Sun-Woo JANG ,  Chang-Yell SHIN ,  Hae-Sun KIM ,  Sang-Min HYUN ,  Yong-Jik KIM ,  Chang-Yong SHIN ,  Jae-Han KIM

IPC: A61K9/70 ,  A61K31/13 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14

Abstract: A percutaneous absorption preparation for the treatment of dementia is disclosed. The percutaneous absorption preparation contains a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains memantine enanthate, a solubilizer, and a pressure-sensitive adhesive. The percutaneous absorption preparation does not form crystal precipitation, shows high skin permeability, allows easy clinical control of the usable patch area, and allows control of the absorption rate by adjusting the rate of release, thus minimizing skin irritation, and provides an economic benefit of minimal waste of the drug while also preventing overdose of the drug.

公开(公告)号：US12156871B2

公开(公告)日：2024-12-03

申请号：US16766112

申请日：2018-11-21

Applicant: SUVEN LIFE SCIENCES LIMITED

Inventor： Ramakrishna Nirogi ,  Anil Karbhari Shinde ,  Abdul Rasheed Mohammed ,  Rajesh Kumar Badange ,  Raghava Choudary Palacharla ,  Venkateswarlu Jasti

IPC: A61P25/28 ,  A61K31/13 ,  A61K31/27 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/445 ,  A61K31/473 ,  A61K31/55 ,  C07D471/04

Abstract: The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the methods of preparation, pharmaceutical composition, combinations and the use of compound formula (I), their stereoisomers, isotopic forms or pharmaceutically acceptable salts thereof.

公开(公告)号：US12151030B2

公开(公告)日：2024-11-26

申请号：US17426796

申请日：2020-01-30

Applicant: HISAMITSU PHARMACEUTICAL CO., INC.

Inventor： Takao Kurokawa ,  Hidekazu Kuma ,  Masaki Yukuhiro

IPC: A61K9/70 ,  A61K31/13 ,  A61K31/27 ,  A61K31/381 ,  A61K31/403 ,  A61K31/407 ,  A61K31/4422 ,  A61K31/573

Abstract: The present invention provides a patch comprising an adhesive layer on a backing, wherein the adhesive layer contains a adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer.

公开(公告)号：US12128017B2

公开(公告)日：2024-10-29

申请号：US17558975

申请日：2021-12-22

Applicant: EMERAMED LIMITED

Inventor： Boyd Eugene Haley ,  Ragnar Axel Theodor Klingberg

IPC: A61K31/166 ,  A61K31/13 ,  A61K31/165 ,  A61K31/198 ,  A61K31/428 ,  A61K31/4745 ,  A61K45/06 ,  A61P25/28

CPC classification number: A61K31/166 ,  A61K31/13 ,  A61K31/165 ,  A61K31/198 ,  A61K31/428 ,  A61K31/4745 ,  A61K45/06 ,  A61P25/28 ,  Y02A50/30 ,  A61K31/13 ,  A61K2300/00 ,  A61K31/165 ,  A61K2300/00 ,  A61K31/166 ,  A61K2300/00 ,  A61K31/428 ,  A61K2300/00 ,  A61K31/4745 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00

Abstract: According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in the therapeutic treatment of a neurodegenerative disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and/or amyotrophic lateral sclerosis.

公开(公告)号：US20240307303A1

公开(公告)日：2024-09-19

申请号：US18675464

申请日：2024-05-28

Applicant: RXOS Medical Inc.

Inventor： Richard M. Millis ,  Jeffrey A. Niezgoda ,  Rajagopalan Sridhar

IPC: A61K9/06 ,  A61K9/00 ,  A61K31/13 ,  A61K31/15 ,  A61K31/216 ,  A61K31/445 ,  A61K33/38 ,  A61K45/06 ,  A61K47/32 ,  A61L15/32 ,  A61L15/44 ,  A61L15/60

CPC classification number: A61K9/06 ,  A61K9/0014 ,  A61K31/13 ,  A61K31/15 ,  A61K31/216 ,  A61K31/445 ,  A61K33/38 ,  A61K45/06 ,  A61K47/32 ,  A61L15/325 ,  A61L15/44 ,  A61L15/60

Abstract: A polyfunctional radical scavenger hydrogel formulation providing extended protection of the extracellular space within a wound site. The polyfunctional radical scavenger hydrogel formulation is generally formed from a hydrogel, a first radical scavenger and a second radical scavenger differing from the first radical scavenger with respect to at least one property. A portion of the first radical scavenger included with the formation and/or second radical scavenger included within the formulation may be dissolved, suspended and/or bonded to a polymer of the hydrogel.

公开(公告)号：US20240299317A1

公开(公告)日：2024-09-12

申请号：US18663524

申请日：2024-05-14

Applicant: ZOGENIX INTERNATIONAL LIMITED ,  BAYLOR COLLEGE OF MEDICINE

Inventor： Bradley S. GALER ,  Stephen J. FARR ,  Thaddeus Cromwell REEDER ,  Jeffrey L. NOEBELS ,  Isamu AIBA

IPC: A61K31/13 ,  A61B5/369

CPC classification number: A61K31/13 ,  A61B5/369

Abstract: Provided are methods of inhibiting spreading depolarization in a subject by administering a sigma-1 agonist or a sigma-1 positive modulator to the subject. In some cases the subject is administered fenfluramine as the sigma-1 positive modulator. In some cases, the subject has been diagnosed with epilepsy, traumatic brain injury, migraines, stroke, ischemic attacks, hypoxia or an increased risk of sudden unexpected death in epilepsy (SUDEP), or a combination thereof.

公开(公告)号：US20240269097A1

公开(公告)日：2024-08-15

申请号：US18419229

申请日：2024-01-22

Applicant: American Ketone LLC

Inventor： Heidi H Hynes

IPC: A61K31/19 ,  A61K31/13 ,  A61K31/198 ,  A61K31/51 ,  A61K35/74 ,  A61K38/39 ,  A61P3/00

CPC classification number: A61K31/19 ,  A61K31/13 ,  A61K31/198 ,  A61K31/51 ,  A61K35/74 ,  A61K38/39 ,  A61P3/00

Abstract: The claimed uses of bioidentical free D-BetaHydroxyButyric Acid as a method (1303), system (1411) and compound for hunger reduction are novel, safe and not anticipated by the body of research spanning well over 75 years. Overall, no adverse findings have been reported within cell, animal and human safety studies at high dose levels with D-BetaHydroxyButyric acid which supports the safety and efficacy of the claimed uses at the anticipated usage levels for the disclosed applications.

公开(公告)号：US20240252491A1

公开(公告)日：2024-08-01

申请号：US18621067

申请日：2024-03-28

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Gretchen SNYDER ,  Robert DAVIS ,  Lawrence P. WENNOGLE

IPC: A61K31/4985 ,  A61K9/00 ,  A61K31/13 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/155 ,  A61K31/165 ,  A61K31/197 ,  A61K31/343 ,  A61K31/36 ,  A61K31/38 ,  A61K31/381 ,  A61K31/42 ,  A61K31/485 ,  A61K31/55 ,  A61K31/5513 ,  A61K38/07 ,  A61P25/24

CPC classification number: A61K31/4985 ,  A61K9/006 ,  A61K31/13 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/155 ,  A61K31/165 ,  A61K31/197 ,  A61K31/343 ,  A61K31/36 ,  A61K31/38 ,  A61K31/381 ,  A61K31/42 ,  A61K31/485 ,  A61K31/55 ,  A61K31/5513 ,  A61K38/07 ,  A61P25/24

Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.

公开(公告)号：US12048680B2

公开(公告)日：2024-07-30

申请号：US17278994

申请日：2019-09-18

Applicant: Kunming Institute of Zoology Chinese Academy of Sciences

Inventor： Yonggang Yao ,  Rongcan Luo ,  Guiyu Li ,  Lingyan Su ,  Jing Yang ,  Dengfeng Zhang

IPC: A61K31/192 ,  A61K31/13 ,  A61K31/24 ,  A61K31/445 ,  A61K31/55 ,  A61K31/702 ,  A61P25/16 ,  A61P25/28

CPC classification number: A61K31/192 ,  A61K31/13 ,  A61K31/24 ,  A61K31/445 ,  A61K31/55 ,  A61K31/702 ,  A61P25/16 ,  A61P25/28

Abstract: A use of Gemifibrozil and a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease. The neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis. Further provided is a pharmaceutical composition for treating and/or preventing a neurodegenerative disease, wherein the pharmaceutical composition comprises Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof, and, preferably, the pharmaceutical composition further comprises one or a plurality of pharmaceutically acceptable carriers. Further provided is a use of the pharmaceutical composition comprising Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease.